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Abstract
Background: Dysfunction of dopaminergic, GABAergic, and glutamatergic function underlies many core symptoms of 
schizophrenia. Combined neonatal injection of the N-methyl-D-aspartate (NMDA) receptor antagonist, phencyclidine (PCP), 
and post-weaning social isolation of rats produces a behavioral syndrome with translational relevance to several core 
symptoms of schizophrenia. This study uses DNA microarray to characterize alterations in hippocampal neurotransmitter-
related gene expression and examines the ability of the sodium channel blocker, lamotrigine, to reverse behavioral changes 
in this model.
Methods: Fifty-four male Lister-hooded rat pups either received phencyclidine (PCP, 10 mg/kg, s.c.) on post-natal days (PND) 
7, 9, and 11 before being weaned on PND 23 into separate cages (isolation; PCP-SI; n = 31) or received vehicle injection and 
group-housing (2–4 per cage; V-GH; n = 23) from weaning. The effect of lamotrigine on locomotor activity, novel object 
recognition, and prepulse inhibition of acoustic startle was examined (PND 60–75) and drug-free hippocampal gene 
expression on PND 70.
Results: Acute lamotrigine (10–15 mg/kg i.p.) reversed the hyperactivity and novel object recognition impairment induced 
by PCP-SI but had no effect on the prepulse inhibition deficit. Microarray revealed small but significant down-regulation of 
hippocampal genes involved in glutamate metabolism, dopamine neurotransmission, and GABA receptor signaling and in 
specific schizophrenia-linked genes, including  parvalbumin (PVALB) and GAD67, in PCP-SI rats, which resemble changes 
reported in schizophrenia.
 International Journal of Neuropsychopharmacology Advance Access published July 15, 2016
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Conclusions: Findings indicate that alterations in dopamine neurotransmission, glutamate metabolism, and GABA signaling 
may contribute to some of the behavioral deficits observed following PCP-SI, and that lamotrigine may have some utility as 
an adjunctive therapy to improve certain cognitive deficits symptoms in schizophrenia.
Keywords: isolation rearing, lamotrigine, microarray, phencyclidine, schizophrenia, glutamate
Introduction
Schizophrenia is a debilitating neuropsychiatric disorder 
with a lifetime incidence of approximately 1% worldwide. 
Schizophrenia is characterized by alterations in three primary 
symptom domains, but has no defining diagnostic neuropa-
thology or predictive biomarkers. Positive symptoms, such as 
auditory and visual hallucinations and delusions, are relatively 
well treated with current antipsychotic medications, but nega-
tive symptoms, including avolition, anhedonia, and cognitive 
dysfunction, which are much less responsive to current therapy 
(Keefe et al., 2007), are a better predictor of therapeutic outcome 
(Leifker et al., 2009). Improved understanding of the neuropa-
thology and molecular mechanisms underlying schizophrenia 
would enhance the probability of identifying new therapeutic 
targets. This process requires development and utilisation of 
robust, reliable rodent models for schizophrenia using behaviors 
with translational relevance and predictive validity (Jones et al., 
2011; Millan and Bales, 2013).
Traditional rodent models for schizophrenia attempt to rep-
licate potential aetiological factors linked to schizophrenia (e.g. 
neurochemical changes, hippocampal disruption, or genetic 
manipulation). For instance, genetic predisposition to schizo-
phrenia has been modelled using mouse gene knock-outs, such 
as DISC1 and NRG1 mutants (Harrison and Law, 2006; Abazyan 
et al., 2010). Disrupting neurogenesis during hippocampal 
development with the antimitotic agent, methylazoxymethanol 
(Lodge and Grace, 2009), or maternal infection by administration 
of the viral mimetic poly(I:C) (Meyer, 2014) during pregnancy 
have been utilized. Early-life adversity is another established 
risk factor modelled using stress protocols, such as post-wean-
ing social isolation of rodents to cause robust behavioral, neu-
robiological, and neurochemical deficits resembling several core 
symptoms in patients with schizophrenia (Fone and Porkess, 
2008; Schubert et al., 2009). Illicit use of N-methyl-D-aspartate 
(NMDA) receptor antagonists, ketamine, and phencyclidine 
(PCP), produces psychosis in humans (Krystal et al., 1994) and 
exacerbates symptoms in schizophrenic patients (Lahti et al., 
1995). Therefore, repeated NMDA receptor antagonist adminis-
tration has been widely used to replicate behavioral and neu-
robiological changes in rodents (Wang et al., 2008; Grayson et 
al., 2015). In particular, neonatal PCP induces long-term locomo-
tor abnormality, cognitive dysfunction (Depoortere et al., 2005), 
impaired sensorimotor gating (Wang et al., 2001) and loss of 
parvalbumin-containing GABAergic neurones accompanied by 
changes in autophagy (Radonjic et al., 2013; Jevtic et al., 2016), 
reminiscent of features of schizophrenia. As no single rodent 
paradigm completely reproduces the diverse schizophrenia 
symptom profile, groups have started to characterize “dual-hit” 
models in rodents to produce more comprehensive and robust 
deficits, in particular of cognitive and negative features (Ashby 
et al., 2010; Gilabert-Juan et al., 2012; Lim et al., 2012; Giovanoli 
et al., 2013; Gaskin et al., 2014; Arcego et al., 2016).
For instance, isolation rearing causes hyper-reactivity 
(increased ambulation) in novel arenas (Ashby et  al., 2010; 
Hickey et  al., 2012; Gaskin et  al., 2014), which is enhanced by 
sub-chronic or neonatal NMDA receptor antagonist administra-
tion (Simpson et al., 2010; Lim et al., 2012). Moreover, neonatal 
PCP produces greater loss of parvalbumin-containing GABAergic 
interneurones (reduced in schizophrenia) than isolation rearing 
(Kaalund et al., 2013). Furthermore, injection of NMDA receptor 
antagonists such as MK-801 or PCP on post-natal days (PNDs) 
7–11 followed by isolation rearing in either Sprague-Dawley or 
Lister-hooded rats enhances the deficit in prepulse inhibition of 
acoustic startle (PPI, a marker of sensori-motor gating impaired 
in schizophrenia) above that seen with either manipulation 
alone (Lim et al., 2012; Gaskin et al., 2014). Subchronic MK-801 
elevated hippocampal GABAA receptor expression in adult rats, 
coincident with isolation-induced elevations in the frontal cor-
tex, but also increased GAT-1 expression in the frontal cortex 
and hippocampus (Hickey et al., 2012), not reported with the lat-
ter. Thus neonatal NMDA antagonist administration may induce 
glutamatergic hypofunction, thought to contribute to nega-
tive and cognitive deficits in schizophrenia not reproduced by 
isolation alone.
Current antipsychotics are high-affinity dopamine D2 recep-
tor antagonists, which is thought to account for their effective-
ness against positive symptoms but have limited benefit against 
negative and cognitive deficits of schizophrenia. Therefore, new 
adjunctive therapeutics operating on novel pharmacological 
targets are essential to improve treatment.
The anticonvulsant drug lamotrigine (prescribed to treat epi-
lepsy and bipolar disorder) blocks voltage-gated sodium chan-
nels (Nav1.2), preventing neuronal depolarization and reducing 
synaptic release of excitatory amino acids, including glutamate 
and aspartate (Leach et al., 1991). In addition, lamotrigine has 
weak inhibitory effects at the 5-HT3, 5-HT1A, and nicotinic ace-
tylcholine receptors (Bourin et  al., 2005; Zheng et  al., 2010). 
Although not approved to treat schizophrenia, clinical studies 
have noted lamotrigine may improve some symptoms in a clo-
zapine-resistant patient population (Goff, 2009; Tiihonen et al., 
2009). Notably, lamotrigine and related voltage-gated sodium 
channel blockers attenuate cognitive deficits in methampheta-
mine- and PCP-treated rats and transgenic mice models used 
to investigate schizophrenia, including visual and spatial learn-
ing (Celikyurt et al., 2012), reversal learning (Large et al., 2011), 
and PPI deficits (Brody et  al., 2003b; Nakato et  al., 2010). The 
mechanisms underlying these pro-cognitive effects are unclear 
but could involve modulation of cortical glutamate release. 
Furthermore, as risperidone also blocks voltage-gated sodium 
channels it is plausible that this mechanism might also under-
lie some of the beneficial effects of this antipsychotic (Brauner 
et al., 2014).
This study characterizes alterations in neurotransmitter 
signaling pathways (in particular dopamine, glutamate, and 
GABA) using microarray and examines the ability of lamo-
trigine to reserve behavioral deficits in rats given combined 
neonatal PCP and isolation rearing, an established neurodevel-
opmental model for schizophrenia. Our aim was to compare 
changes in hippocampal gene expression with those reported 
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in schizophrenia and our prediction was that lamotrigine would 




Eight litters of three-day old, male Lister hooded rat pups 
(n = 54) were obtained from Charles River UK, accompanied by 
their natural dam. On PNDs 7, 9, and 11, half of the pups from 
each litter were treated with phencyclidine hydrochloride (PCP; 
Sigma-Aldrich) dissolved in 0.154 M sterile saline (10 mg/kg s.c.) 
and the rest were treated with saline (1 ml/kg), as described pre-
viously (Gaskin et al., 2014; Watson et al., 2016). To avoid mater-
nal rejection of pups, hands were washed and rubbed in bedding 
material prior to injection and photographic records of pelage 
were used for identification and to avoid repeated marking. Pups 
were monitored for 3 h following injection and only disturbed to 
return to the nest if separated from the dam. Pups were weaned 
by litter on PND 23, and those receiving saline were housed in 
groups of 3–4 (32 x 51 cm polycarbonate cages with metal grid 
lids, V-GH, n = 23), while PCP-treated pups were housed alone 
in social isolation (25 x 42cm cages, PCP-SI, n = 31) for the entire 
study. V-GH and PCP-SI rats were housed in the same holding 
room, enabling visual, auditory, and olfactory contact. Cages 
contained sawdust bedding (but no environmental enrich-
ment) changed once per week when each rat was weighed, but 
rats were otherwise undisturbed until behavioral testing com-
menced five weeks later. Rats had free access to water and food 
(BeeKay Standard Laboratory Diet, BioSystems), and were main-
tained on a 12 h light dark cycle (lights on 0700 h) in controlled 
humidity (45 ± 15%). Rats were divided into two groups to exam-
ine the impact of lamotrigine on behavior (V-GH, n = 15; PCP-SI, 
n  =  23), or the effect of developmental manipulation (PCP-SI) 
on gene expression by microarray. In the microarray study rats 
only underwent locomotor assessment (to confirm develop-
ment of the isolation syndrome) to prevent further behavio-
ral assessment affecting microarray data (V-GH, n = 8; PCP-SI, 
n  =  8). In both groups, natural brothers were paired for treat-
ment, to minimize the impact of genetic variation on outcome. 
All procedures were carried out in accordance with the Animals 
(Scientific Procedures) Act, 1986, with University of Nottingham 
ethical committee approval and in accordance with the ARRIVE 
guidelines.
Experimental Design and Drugs
All studies were performed on rats that received both neonatal 
PCP and subsequent social isolation or vehicle-treated group-
housed littermates. The independent impact of exposure to 
each of these two developmental manipulations has been 
thoroughly studied before (for reviews see Fone and Porkess 
[2008] and Grayson et al. [2015]) and compared with the com-
bined treatment by us (Gaskin et al., 2014; Watson et al., 2016). 
The current study was designed to compare the ability of lamo-
trigine to reverse the resultant behavioral syndrome but not to 
determine which alterations were produced by either neonatal 
PCP or isolation alone. To reduce unnecessary use of animals, 
in accordance with the 3Rs principle and the ARRIVE guide-
lines, separate groups (PCP or isolation rearing alone) were not 
included in this study. To ascertain any potential confounding 
motor effect of lamotrigine, indices of locomotor activity were 
carefully monitored in each behavioral task and findings are 
discussed later. Lamotrigine (Sigma-Aldrich) was suspended 
in 50% w/v methylcellulose, containing 1M HCl adjusted to 
pH 7.4 with 0.1M NaOH. Prior to behavioral testing, rats were 
divided into lamotrigine or control groups by drawing lots, such 
that PCP-isolation-reared rats (hereafter referred to as PCP-SI) 
received either vehicle (2 ml/kg, PCP-SI-V, n = 8) or a low dose 
(10 mg/kg, PCP-SI-L10, n = 8) or high dose (15 mg/kg, PCP-SI-L15, 
n = 7) of lamotrigine and group-housed perinatal saline-treated 
(hereafter V-GH) rats received either vehicle (V-GH-V, n = 8) or a 
high dose of lamotrigine (15 mg/kg, V-GH-L15, n = 7). All treat-
ments were administered by intraperitoneal injection (2 ml/kg) 
60 min before each behavioral test. Doses of lamotrigine were 
selected from previous rat cognitive behavioral studies (Brody 
et al., 2003b; Celikyurt et al., 2012).
Behavioral Testing
Behavior was examined (between 0900 to 1600h) in a battery of 
tasks selected for translational relevance to positive (locomotor 
activity in a novel arena) and cognitive (novel object recogni-
tion [NOR] and PPI) symptoms of schizophrenia, in order of least 
to most aversive to minimize the impact of the previous test 
on the subsequent assessment. In all cases rats were acclima-
tized to the behavioral room for at least 30 min before testing, 
the apparatus was cleaned between each use with 20% alcohol, 
and the observer was unaware of drug treatment. Behavioral 
observations commenced on PND 63 using identical protocols 
to those described previously (King et al., 2004; Schubert et al., 
2009; Watson et al., 2012, 2016; Gaskin et al., 2014).
Locomotor Activity
In order to assess the exploratory response to a novel arena, 
which is recognized as a valid marker for positive symptoms 
sensitive to antipsychotic treatment (Fabricius et al., 2010; Jones 
et al., 2011; McIntosh et al., 2013), open field locomotor explora-
tory activity (LMA) was recorded in infrared activity chambers 
(clear Perspex boxes 39 x 23.5 x 24.5cm). Rats were assigned indi-
vidual chambers crossed by infrared beams (Photobeam Activity 
System, San Diego Instruments) to measure horizontal ambula-
tory movements as number of beams broken in 10 min bins for 
1 h (Bianchi et al., 2006; Jones et al., 2011).
Novel Object Recognition
To assess visual learning and memory, a simple two-trial NOR 
discrimination task with established translational relevance 
to visual recognition memory impaired in schizophrenia (Lyon 
et al., 2012; Rajagopal et al., 2014) was used 24 h after locomotor 
assessment. Each rat being assigned to the same chamber previ-
ously used. Rats were placed in their chamber for 3 min acclima-
tisation, before returning to their home cage for 1 min to enable 
two identical objects (8 cm high plastic bottles, 5 cm diameter, 
filled with water and secured to the floor by blue-tac) to be intro-
duced. Rats were then returned to chamber, and exploration of 
each object recorded separately for 3 min (familiarization, trial 
1). For 2 h rats were returned to their home cage, and one object 
selected in a pseudo-random manner replaced with a visually 
distinct novel object (identical size bottle covered in three rings 
of 2 cm black tape). During the second 3 min choice trial (trial 
2) object exploration, directed attention to each object with the 
nose ≤1 cm away (accompanied by sniffing with active vibrissae), 
was recorded using stop watches. Climbing on or chewing the 
object was not recorded as active exploration.
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In addition to comparing the actual time (s) exploring the 
novel and familiar objects in the choice trial the discrimina-
tion ratio (D2) was calculated [novel object exploration/(novel 
+ familiar) object exploration time] as an index of preferential 
object exploration independent of total exploration time.
Prepulse Inhibition of Acoustic Startle
To assess changes in sensorimotor gating, which shares a neurobi-
ological equivalence and is thought to map to the pre-attentional 
processing cognitive domain in humans, rats were examined in 
a prepulse inhibition of acoustic startle test. PPI was recorded in 
computerized startle boxes (San Diego Instruments) as described 
previously (Schubert et al., 2009; Jones et al., 2011). After acclimati-
zation to white background noise (65 dB, 5 mins), rats received 66 x 
120 dB tones (40 ms in duration) either delivered alone or preceded 
by a 20 ms prepulse of 72, 76, 80, or 84 dB with an unpredictable 
inter-trial interval (10–20 s). The startle amplitude to tone alone 
(first ten and last ten startles) was compared to calculate habitu-
ation, and used to calculate the average percentage inhibition of 
startle (%PPI) for each prepulse-pulse combination. Previous stud-
ies by our group have shown that startle responses to 72 dB tri-
als fail to significantly attenuate PPI, but exclusion of these trials 
leads to greater variation in response to other prepulse intensities, 
so the data from 72 dB prepulse trials were collected, but excluded 
from analysis. A conditional statement was included in the analy-
sis software to automatically exclude any trial whose %PPI was >2 
standard deviations from the mean, which could occur due to rat 
movement during startle exposure.
RNA Isolation for DNA Microarray
On PND 70, following locomotor activity assessment (see above) 
rats in the microarray study were culled by concussion followed 
by immediate decapitation to collect the whole left hippocam-
pus, which was frozen in liquid nitrogen in RNAse-free tubes 
(Corning). Using sterile dissection, RNA was isolated using TRI 
Reagent (Sigma-Aldrich). Sample concentration and purity 
was tested using nanodrop and Bioanalyser 2100 (Agilent) 
and 14 samples (two rats with low RNA yield were excluded) 
were selected from three litters, divided so natural brothers 
were paired across the two treatment groups to minimize the 
impact of natural genetic variation on analysis. RNA samples 
were hybridized onto Affymetrix GeneChip Rat Exon Gene 1.0 
ST microarrays (Affymetrix) and subsequently analyzed at the 
Hospital for Sick Children in Toronto, Canada.
Prior to conducting the microarray analysis, published litera-
ture was used to identify a list of candidate genes based on their 
known biological, neurophysiological, or functional relevance to 
schizophrenia, with the knowledge that any of these showing 
the greatest differential expression from microarray analysis 
would be selected for further Q-PCR analysis. As this approach 
would limit analysis to the existing theoretical neurobiology of 
the disorder, we also planned to select genes with the highest 
differential expression that were in key regulatory positions in 
any canonical pathways also identified as affected. Microarray 
data was analyzed to determine change in expression meet-
ing lenient critical thresholds of a combined change in expres-
sion (p < 0.05) and a q-value <55%. Genes meeting criteria were: 
(i) entered into the Ingenuity Pathway Analysis software (IPA, 
Ingenuity Systems Inc., QIAGEN) for further investigation and 
(ii) selected for subsequent analysis by quantitative PCR. For this 
purpose, total RNA was reverse transcribed with SuperScript 
III and random primers (Promega UK). Q-PCR reactions were 
performed in triplicate with the SensiMix Plus SYBR Green PCR 
kit (Bioline) and a Rotor Gene 3000 cycler (Corbett Life Science, 
Qiagen UK). Q-PCR primers were designed with Primer3 (www.
genome.wi.mit.edu/cgi-bin/primer/primer3.cgi) and optimized 
in-house (Table  1) both for the genes of interest and control 
housekeeping genes (HPRT1, PGK1, GAPDH).
Statistical Analysis
Microsoft Excel 2007, GraphPad Prism v6 (GraphPad Software 
Inc.) and InVivoStat were used for statistical analyses. Data were 
checked for normality and homogeneity of variance using Shapiro-
Wilk’s and Levene’s tests, respectively. LMA, NOR, and PPI data were 
analyzed by three-way repeated measures analysis of variance (RM 
ANOVA, with rearing condition and drug challenge as main fac-
tors, and time, object, or pre-pulse volume as the repeated meas-
ure). Choice trial discrimination ratio was analyzed by two-way 
ANOVA (with pre-exposure and drug challenge as factors). In each 
case, where appropriate, multiple comparison post hoc tests were 
used where ANOVA suggested statistical significance (considered 
p < 0.05). Q-PCR results were analyzed using REST 2009 software 
(QIAGEN and Technical University) to give relative fold-changes 
in gene expression and a p-value confidence interval. All data are 
presented as mean ± SEM and p < 0.05 was considered significant.
Results
Effect of Lamotrigine on PCP-SI-Induced Changes in 
Locomotor Activity
As expected, when placed in a novel arena, horizontal activ-
ity gradually decreased in all groups, reflecting habituation to 
the mildly aversive environment, supported by a significant 
main effect of time [F(11,352) = 93.408, p < 0.001]. Isolation-reared 
rats were significantly more active than group-reared counter-
parts, reflected by a significant main effect of housing condition 
[F(1,32) = 4.570, p = 0.040]. Despite there being no overall significant 
effect of lamotrigine on locomotor activity [F(2,31) = 2.985, p = 0.065], 
there was a significant housing x drug interaction [F(1,31) = 5.501, 
p = 0.025] over the 60 min session, reflecting a reduction in activ-
ity due to lamotrigine treatment in the isolation-reared animals 
only (Figure 1A). Furthermore, two-way ANOVA of total activity 
during the first 30 min (where activity differences were most 
marked, as often found in isolation studies; Bianchi et al., 2006; 
Fabricius et  al., 2010; McIntosh et  al., 2013) revealed a signifi-
cant rearing x drug interaction [F(1,32) = 6.719, p = 0.014], but no 
main effect of either rearing condition or drug treatment alone 
(Figure 1B). Of note, post hoc analysis confirmed there was a sig-
nificant increase (p < 0.05) in locomotion in PCP-SI-V compared 
to control V-GH-V rats, which was significantly reduced (p < 0.05) 
by the highest dose of lamotrigine (PCP-SI-L15) compared to that 
in PCP-SI-V rats. Taken together, this suggests isolation rearing 
induced mild hyperactivity that was partially reversed by lamo-
trigine, most notably at the highest dose.
To confirm development of the isolation syndrome in rats 
utilized for microarray analysis, PCP-SI reared rats in this study 
also displayed significantly elevated LMA (p = 0.0275) compared 
to V-GH controls in the activity chambers (data not shown).
Effect of Lamotrigine on PCP-SI-Induced Deficits in 
Novel Object Recognition
To determine any impact of neurodevelopmental manipulation or 
acute drug treatment on visual learning and memory, rats were 
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examined in the NOR paradigm. During the second (choice) trial, 
ANOVA showed a main effect of object [F(1,32) = 64.72, p < 0.0001] 
and a significant object x treatment interaction [F(4,29)  =  4.620, 
p  =  0.0045], but no main effect of drug treatment [F(4,29)  =  2.064, 
p  = 0.1081; Figure 2A]. Group-housed vehicle control rats readily 
discriminated the objects during the choice trial, irrespective of 
subsequent acute injection of vehicle or lamotrigine, spending sig-
nificantly more time (p < 0.001) exploring the novel than the famil-
iar object, while isolated rats given vehicle (PCP-SI-V) or high dose 
lamotrigine (PCP-SI-L15) did not (p > 0.05). Of note, isolated rats 
receiving lamotrigine at 10 mg/kg (PCP-SI-L10) spent significantly 
longer exploring the novel object (p < 0.001), showing that this dose 
reversed the NOR impairment induced by PCP-isolation-rearing.
Consistent with the raw data, there was a highly signifi-
cant main effect of rearing condition [F(1,31) = 25.731, p < 0.001] 
and drug treatment [F(2,30) = 9.795, p < 0.001] but no interaction 
between the two [F(1,31) = 0.844, p = 0.365] on the D2 discrimina-
tion ratio. Thus the D2 ratio was significantly lower in PCP-SI-V 
than V-GH-V (p  <  0.01), and 10 mg/kg lamotrigine rats (PCP-
SI-L10) had a significantly higher D2 ratio than PCP-SI-V rats 
(p < 0.01; Figure 2B).
Consistent with interpretation that the effect of isolation 
and lamotrigine on NOR were specifically due to changes in 
learning and memory, no object preference was observed during 
the familiarization trial, and no change in total object explora-
tion occurred between any groups during the choice trial (data 
not shown). Thus both isolation and lamotrigine caused a redis-
tribution of exploration towards the unfamiliar object and not 
a non-specific reduction in overall object investigation in the 
choice trial.
Figure 1. Lamotrigine attenuated PCP-SI rearing induced hyperlocomotion in a novel arena, without reducing horizontal activity in V-GH controls. (A) Locomotor beam 
breaks (mean ± SEM in consecutive 10 min epochs, n = 7–8) significantly decreased over 60 min [F(11,352) = 93.408, p < 0.001, RM ANOVA], reflecting habituation to a novel 
arena. Rearing in social isolation (PCP-SI) significantly increased activity compared to group housed (V-GH) controls [F(1,32) = 4.570, p = 0.040, RM ANOVA], which was 
reversed by lamotrigine at 15 mg/kg i.p. (L15) but not 10 mg/kg i.p. [L10; housing x drug interaction, F(1,31) = 5.501, p = 0.025, RM ANOVA]. **p < 0.01 from PCP-SI-L15 lamo-
trigine, Bonferroni’s post hoc following ANOVA. PCP-SI, phencyclidine-treated pups housed alone in social isolation. (B) Total locomotor counts during the first 30 min 
were elevated in PCP-SI rats and were significantly attenuated by lamotrigine (15 mg/kg), without any accompanying decrease in locomotion in V-GH-L15 rats treated 
with the same dose. *p < 0.05 from V-GH-V controls and #p < 0.05 from PCP-SI-V rats, Bonferroni’s post hoc test following ANOVA.
Table 1. Primer Sequences for Q-PCR Analysis
Gene Name Forward Primer Reverse Primer Product Size (bp)
Housekeeping Genes
Hprt1 cgaggagtcctgttgatgttgc ctggcctataggctcatagtgc 172
Pgk1 tagtggctgagatgtggcacag gctcacttcctttctcaggcag 166
GAPDH ggcaagttcaatggcacagt tggtgaagacgccagtagactc 183
Genes of Interest from Microarray
DDC gcctgattcctttcttcgtg acgccattcagaagataccg 175
DRD5 agacacggtcttccacaagg cacagtcaagctcccagaca 185
GABBR1 caagagcgtgtccactgaaa gcacaaagagcacaaccaga 191
GABRB2 ctgggtctccttttggatca ccagaagggccataaagaca 185
GABRA4 ggacagtttgctggatggtt tggggccatcatatttcagt 185
GAD1 cacaaactcagcggcataga gccttgtcccctgtatcgta 194
GAT ggggccttcctaattccata gtagatggcccaggagatga 210
PVALB gagtgcggatgatgtgaaga gtcagcgccacttagctttc 228
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Effect of Lamotrigine on PCP-SI-Induced Attenuation 
of Prepulse Inhibition of Acoustic Startle
As expected, inhibition of the acoustic startle progressively 
increased with prepulse intensity irrespective of neurodevelop-
ment condition or drug treatment. However, %PPI was lower in 
PCP-SI-V rats than in any other group at all prepulse intensities, 
such that ANOVA showed a significant main effect of prepulse 
[F(2,64)  =  105.060, p  <  0.001] and rearing condition [F(1,32)  =  4.447, 
p  =  0.043]. However, PCP-SI-rearing only significantly reduced 
%PPI at the 76 dB prepulse level (V-GH-V vs. PCP-SI-V, p < 0.05). 
The trend for %PPI to be increased by lamotrigine in the PCP-
SI-L10 compared to the PCP-SI-V controls, most notably at 84 dB 
prepulse intensity, was not significant [F(2,33) = 0.284, p = 0.754], 
and there was no rearing x lamotrigine interaction [F(1,32) = 0.437, 
p = 0.513; Figure 3].
There was no significant effect of either rearing condition 
or lamotrigine, nor any interaction on the initial startle ampli-
tude nor habituation to the 120 dB startle alone, confirming that 
observed effects were not confounded by any non-specific drug 
effect on the startle response (data not shown).
PCP-SI-Induced Changes in Gene Expression
Microarray gene-expression profiling in the whole hippocampus 
(selected because of inferred relevance of this area to the neuro-
biological aetiology of schizophrenia and known neurochemical 
changes with isolation rearing in the rat) identified a total of 715 
genes that were differentially expressed by the criteria defined 
in the methods. From these genes, only two were up-regulated, 
while 713 were down-regulated (Supplementary Table S1 and 
Table 2). A pathway analysis of the microarray gene-expression 
data identified the most likely biological systems and pathways 
perturbed by combined PCP and isolation. Of particular note, the 
most significantly affected pathways included glutamate metab-
olism and GABA and dopamine receptor signaling. Importantly, 
within each of these canonical pathways were genes either 
encoding proteins involved in rate limiting steps (e.g. glutamate 
decarboxylase and dopa decarboxylase) or transporters (GABA 
transporter) or receptors (GABAB) that have genetic associa-
tions as risk factors for schizophrenia (Harrison, 2015). In addi-
tion, IPA analysis indicated that PCP-SI altered several additional 
genes coding proteins (e.g. parvalbumin, neurotensin, and the 
5-HT5A receptor) previously associated by multiple techniques 
to changes seen in patients with schizophrenia (Beasley and 
Reynolds, 1997; Sharma et al., 1997; Iwata et al., 2001; Hashimoto 
et al., 2003; Table 2). The microarray data (Supplementary Table 
S1) also identified four gamma subunits of the L-type voltage-
gated calcium channels to be down-regulated in PCP-SI rats, 
which will be discussed later. Of note, 34 genes encoding olfac-
tory receptors and 3 encoding vomeronasal receptors (thought 
to respond to pheromones) were also down-regulated, but these 
changes may relate to the impact of social isolation on olfactory 
processes and have no relevance to changes in phenotype rel-
evant to schizophrenia.
From the microarray results, seven candidate differentially 
expressed genes (DEGs) of interest were selected for Q-PCR 
analysis which were  from each of the three canonical pathways 
affected by PCP-SI. The DEGs were: GAD1 (glutamate metabo-
lism to GABA); GABBR1, GABRA4, GABRB2, and SLC6A1 (GABA 
receptor signaling); and DRD5 and DDC (dopamine receptor 
signaling). These particular genes were selected because of their 
known association with schizophrenia (Allen et al., 2008; Ripke 
et al., 2013) and identification of their relative expression change 
from the current rat microarray data. Furthermore, Q-PCR was 
used to identify any change in expression of PVALB, previously 
known to be altered in the post-mortem brains of schizophrenia 
patients (Hardingham and Do, 2016), and by isolation rearing in 
the rat (Harte et al., 2007). Q-PCR analysis of these seven genes 
failed to show any significant alterations in gene expression 
when normalized to three housekeeping genes whose expres-
sion was unchanged in control and PCP-SI hippocampi (data not 
shown).
Figure 2. Impairment in novel object recognition (NOR) discrimination follow-
ing PCP-SI rearing was reversed by lamotrigine treatment at 10 mg/kg. (A) Irre-
spective of whether they received acute treatment with 15 mg/kg lamotrigine 
(V-GH-L15) or vehicle (V-GH-V), group-housed rats preferentially explored the 
novel over the familiar object (s, mean ± SEM, n = 7–8) during the second choice 
trial during the NOR task [significant object x treatment interaction by two-way 
ANOVA, F(4,29)  =  4.620, p  =  0.0045]. While vehicle-treated PCP-isolation reared 
rats (PCP-SI-V) could spent an equal time exploring both objects, discrimina-
tion of the novel object was restored following acute treatment with the highest 
dose (15 mg/kg) of lamotrigine (PCP-SI-L15). PCP-SI-reared rats receiving 10 mg/
kg lamotrigine (PCP-SI-L10) were able to discriminate between the two objects. 
**p < 0.001 novel vs familiar, Bonferroni’s post-hoc test following ANOVA. PCP-SI, 
phencyclidine-treated pups housed alone in social isolation. (B) The D2 discrimi-
nation ratio (novel/novel + familiar times, mean ± SEM, n = 7–8) was significantly 
affected by PCP-SI-rearing [F(1,31) = 25.731, p < 0.001] and lamotrigine [F(2,30) = 9.795, 
p < 0.001], such that Bonferroni’s post hoc test showed a significant impairment 
in PCP-SI-V rats, **p < 0.01 from V-GH-V by was reversed by 10 mg/kg lamotrigine, 
#p < 0.01 from PCP-SI-V following ANOVA.
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Discussion
Overall, this study offers a new insight into the behavioral con-
sequences and associated genetic background to complex neu-
rodevelopmental alterations induced by combined neonatal PCP 
administration and isolation rearing of the rat, using animals 
paired by litter to minimize the impact of natural genetic vari-
ation. The results of the microarray suggest significant altera-
tions in gene expression occur in three key neurotransmitter 
pathways believed to have relevance to the aetiology of schiz-
ophrenia. The implication that dopaminergic and GABAergic 
signaling, as well as glutamate metabolism, may be involved in 
the behavioral outcomes of combined PCP-SI treatment is sim-
ilar to numerous findings in humans (Hashimoto et  al., 2003; 
Benes et al., 2007; Howes and Kapur, 2009; Howes et al., 2012) 
and suggests the utility of this neurodevelopmental model to 
investigate the neurobiology of schizophrenia.
A large meta-analysis (Goff, 2009; Tiihonen et al., 2009) iden-
tified the potential benefit of lamotrigine to treat psychosis and 
schizoaffective disorder (Erfurth et al., 1998), in particular in 
clozapine-resistant patients, although other studies have failed 
to replicate this effect (Reid et al., 2013; Vayisoglu et al., 2013). 
In this study, lamotrigine significantly reduced hyperactivity in 
PCP-SI rats placed in a novel arena, a potential index of positive 
symptoms of schizophrenia (Fone and Porkess, 2008; Fabricius 
et al., 2010), but had no effect in V-GH littermates. In previous 
studies, the novelty-induced hyperactivity seen in GluA1 AMPA 
subunit knockout mice was suppressed following a 28 day die-
tary administration of lamotrigine (Maksimovic et al., 2014). 
Furthermore, Williams and colleagues (2006) showed combined 
administration of clozapine with lamotrigine significantly 
reduced acute PCP-induced hyperlocomotion. This data is con-
sistent with clinical studies showing the benefit of combined 
clozapine and lamotrigine treatment on positive and negative 
symptoms in schizophrenia (Tiihonen et al., 2009). Lamotrigine 
reduces excitability in striatal neurons in vitro (Calabresi et al., 
1999) by blockade of pre-synaptic voltage-gated sodium chan-
nels which attenuate neurotransmitter release (Leach et al., 
1991). A similar attenuation of mesolimbic dopamine release 
could explain its ability to reduce hyperactivity in PCP-SI-rats 
and the psychosis in schizophrenia patients (Abi-Dargham et al., 
2000), both thought to result from overactivity of the mesolimbic 
pathway. A recent study showed lamotrigine modulates phos-
phorylation of and disrupts the same βarr2/Akt/GSK3 signaling 
complex that is coupled to D2 dopamine receptors and was una-
ble to suppress novelty-induced hyperactivity in βarr2-KO mice 
(Del’ Guidice and Beaulieu, 2015). This suggests lamotrigine may 
directly interfere with dopamine D2-mediated signaling in vivo 
but also that it might have limited use as an adjunct therapy 
with existing antipsychotics whose therapeutic effect on posi-
tive symptoms is likely to involve the D2 receptor antagonism.
Both isolation-rearing (Jones et al., 2011; Watson et al., 2012; 
McIntosh et al., 2013) and repeated PCP-injection to adult rats 
(McKibben et  al., 2010; Grayson et  al., 2015) impair NOR, as 
does combined PCP-SI (Gaskin et al., 2014; Watson et al., 2016), 
consistent with findings in this study. Lamotrigine at the low 
(10 mg/kg i.p.) but not high dose restored the PCP-SI-induced 
impairment in NOR in this study. Few studies have examined 
Figure 3. Impairment in prepulse inhibition (PPI) of acoustic startle response (at 76–84 dB prepulse intensity as indicated) by PCP-SI rearing was not reversed by 
lamotrigine treatment. PCP-SI reared rats (PCP-SI-V) demonstrated a significant impairment in PPI response (mean ± SEM, n = 7–8) compared to group-housed vehicle-
treated littermates [V-GH-V; F(1,32) = 4.447, p = 0.043, RM ANOVA]. The reduction in startle response was not reversed by lamotrigine treatment at either 10 (PCP-SI-L10) or 
15 mg/kg (PCP-SI-L15), and there were no between-factor interactions. *p < 0.05 from V-GH-V, Bonferroni’s post hoc test following ANOVA. PCP-SI, phencyclidine-treated 
pups housed alone in social isolation.
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the effect of lamotrigine on cognition, but in mice at 40 mg/kg 
i.p. it prolonged the time in the learned quadrant in a Morris 
Water Maze probe trial of retention and improved latency in a 
passive avoidance test (Celikyurt et al., 2012). In contrast, lamo-
trigine did not cause any significant change in working memory 
performance (Shannon and Love, 2004) or attention in a five-
choice serial reaction time task in rats (Shannon and Love, 2005).
Interestingly, the impairment in PPI in mGluR1 knock-out 
mice (Brody et  al., 2003a) and methamphetamine-induced PPI 
deficits (Nakato et al., 2010) were both reversed by acute lamo-
trigine treatment, although amphetamine-induced deficits were 
not (Brody et al., 2003b). The current results don’t replicate these 
reports since the PCP-SI-induced deficit in PPI was unaffected by 
lamotrigine; however, previous publications used higher doses 
(27–30 mg/kg) than herein. The current data are also consistent 
with our earlier findings (Gaskin et  al., 2014) that PPI deficits 
induced by this dual-hit (neonatal PCP and isolation) treatment 
are more substantial than seen with isolation alone.
Previous microarray analysis of the prefrontal cortex 24 h 
after perinatal PCP identified alterations in expression of 
genes involved in cell survival and apoptosis (Liu et al., 2010). 
PCP caused acute changes in  brain derived neurotrophic fac-
tor (BDNF) and NMDAR1, akin to prefrontal changes seen in 
schizophrenia patients and some rodent models for the disorder 
(Beasley and Reynolds, 1997; Liu et al., 2010). Previous microar-
ray studies found altered expression of the NR2A NMDA recep-
tor subunit and development-related genes (e.g. NURR1) in the 
prefrontal cortex (Turnock-Jones et al., 2009) and the dentate 
gyrus (Ibi et al., 2008) of isolation-reared rodents. However, this 
is the first study to report long-term effects of neonatal PCP (and 
isolation rearing) on gene expression.
Ingenuity Pathway Analysis herein clearly identified altera-
tions in three canonical pathways, which are highly relevant to 
changes thought to occur in schizophrenia. A central tenet of 
schizophrenia aetiology is alteration in dopaminergic pathology 
in mesolimbic and mesocortical pathways (Howes and Kapur, 
2009; Howes et al., 2012), so the observation that dopamine 
signaling was significantly affected by PCP-SI is not surprising. 
Dopamine projections to the hippocampus are sparse but thought 
to regulate ventral cholinergic projections to the nucleus accum-
bens (nAcc; Floresco et al., 2001) and a feedback loop from the 
ventral tegmental area to the ventral hippocampus is implicated 
in object-based memory formation through long-term poten-
tiation and long-term depression. The current microarray find-
ing that the DRD5 gene encoding the dopamine D5 receptor was 
down-regulated, together with two variants of adenylate cyclase, 
the down-stream effector of this G-protein receptor, is particu-
larly interesting. The 1.24-fold decrease in the DDC gene reported 
herein in PCP-SI rats is also unsurprising. Polymorphisms in 
DDC, the gene the encoding dopa decarboxylase which converts 
L-DOPA into dopamine, have been associated with the age of 
onset of schizophrenia in male patients (Borglum et al., 2001), 
although other studies found no association in paranoid schizo-
phrenia (Hoogendoorn et al., 2005; Talkowski et al., 2008).
Table 2. Selection of Genes of Interest
Gene Symbol Gene Assignment p-value q-value (%) Fold Change
Glutamate Metabolism Pathway
Gad1 glutamate decarboxylase 1 0.0284 47.72 -1.08
Gpt2 glutamic pyruvate transaminase (alanine aminotransferase) 2 0.0225 43.10 -1.08
Nadsyn1 NAD synthetase 1 0.0396 50.52 -1.08
Abat 4-aminobutyrate aminotransferase 0.0041 25.15 -1.06
Aldh5a1 aldehyde dehydrogenase 5 family, member A1 0.0239 43.10 -1.06
Glud1 glutamate dehydrogenase 1 0.0143 37.73 -1.05
GABA Receptor Signaling Pathway
Gabra4 gamma-aminobutyric acid (GABA) A receptor, alpha 4 0.0085 32.49 -1.08
Gabrb2 gamma-aminobutyric acid (GABA) A receptor, beta 2 0.0065 27.96 -1.08
Slc6a1 solute carrier family 6 (neurotransmitter transporter, GABA), member 1 0.0291 47.72 -1.04
Gabbr1 gamma-aminobutyric acid (GABA) B receptor 1 0.0265 47.72 -1.03
Also in pathway: Abat, Aldh5a1, Gad1 (see above)
Dopamine Receptor Signaling Pathway
Ddc dopa decarboxylase (aromatic L-amino acid decarboxylase) 0.0150 37.73 -1.24
Drd5 dopamine receptor D5 0.0265 47.72 -1.13
Gnal guanine nucleotide binding protein, alpha activating activity polypeptide, 
olfactory type
0.0253 43.10 -1.13
Adcy1 adenylate cyclase 1 (brain) 0.0303 47.72 -1.10
Prkar2a protein kinase, cAMP dependent regulatory, type II alpha 0.0209 43.10 -1.07
Ppp2r3a protein phosphatase 2 (formerly 2A), regulatory subunit 0.0482 54.56 -1.06
Adcy2 adenylate cyclase 2 (brain) 0.0036 25.15 -1.06
Prkar1b protein kinase, cAMP dependent regulatory, type I, beta 0.0433 50.52 -1.04
Other Down-Regulated Genes of Interest
Nts neurotensin 0.0064 27.96 -1.44
Npsr1 neuropeptide S receptor 1 0.0022 23.21 -1.18
Htr5a 5-hydroxytryptamine (serotonin) receptor 5A 0.0186 40.47 -1.11
Pvalb parvalbumin 0.0048 25.15 -1.10
Up-Regulated Genes
Csrp2 cysteine and glycine-rich protein 2 0.0001 9.75 1.15
Olr1459 olfactory receptor 1459 0.0001 9.75 1.11
Genes were selected based on differential expression in the hippocampus of PCP-SI rats compared to vehicle treated group-housed littermate controls by microarray 
analysis, following the selection criteria p < 0.05, q-val < 55%
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The role of glutamate in schizophrenia has been widely stud-
ied and is thought to contribute to the negative and cognitive 
deficits. In the current study, glutamate signaling was relatively 
unaffected by PCP-SI, with none of the NMDA receptor subunits 
being differentially expressed, although genes coding proteins 
involved in glutamate metabolism were significantly affected. 
Specifically, six genes encoding enzymes regulating glutamate 
metabolism were significantly down-regulated in PCP-SI rats, 
as well as one gene encoding the transporter protein, SLC1A3 
(Solute carrier family 1 member 3, aka Glutamate Aspartate 
Transporter or Excitatory Amino Acid Transporter 1; Table  2). 
It is unclear if down-regulation of these genes is a compensa-
tory result of lower basal glutamate in PCP-SI rats or a direct 
consequence of the developmental manipulation. Of particular 
note, GAD67 (aka Glutamate Decarboxylase 1, 67kDa isoform), 
encoding the enzyme which converts glutamate to GABA, is 
down-regulated in both the hippocampi (Benes et al., 2007) and 
cortices (Hashimoto et al., 2003) of schizophrenia patients and 
the medial pre-frontal cortices of rats injected with MK-801 on 
PND 7 and socially isolated post-weaning (Gilabert-Juan et al., 
2012). Similarly, ketamine application to cultured hippocampal 
neurons caused a dose-dependent decrease in GAD67 immuno-
reactivity in parvalbumin-expressing GABAergic interneurons 
(Kinney et al., 2006), but this is the first study to suggest similar 
changes occur following neonatal PCP.
Interestingly, neonatal PCP alone decreases the sensitivity to 
a GAT1 inhibitor (Kjaerby et al., 2014), consistent with the micro-
array data herein showing decreased expression of the GABA 
transporter gene SLC6A1 (Table 2). A variety of GABA-associated 
genes were also down-regulated by PCP-SI treatment, including 
the PVALB gene encoding parvalbumin and three GABA recep-
tor subunit genes (GABBR1, GABRA4, GABRB2; Table 2, Figure 4). 
Impaired GABAergic inhibition of hippocampal neural activity 
is emerging as a key feature of schizophrenia (Lisman et al., 
2008; Heckers and Konradi, 2010). Patients have altered post-
mortem levels of markers of GABA neurone integrity and par-
valbumin (Beasley and Reynolds, 1997; Heckers and Konradi, 
2010). Imaging studies also show hippocampal metabolic hyper-
activity (Heckers et al., 1998; Tamminga et al., 2010; Schobel et 
al., 2013; Tregellas et al., 2014) in patients with schizophrenia, 
which may contribute to excitotoxic volume reduction (Adriano 
et al., 2012). Consistent with these human findings, isolation-
reared rats have loss of parvalbumin-positive GABAergic neu-
rones (Harte et al., 2007) and reduction in markers of dendrites, 
synapses (Varty et al., 1999), and microtubular proteins (Bianchi 
et al., 2006), together with impaired GABA release, measured 
using magnetic resonance spectroscopy (Napolitano et al., 
2013), which may cause decreased hippocampal plasticity and 
function. Q-PCR analysis failed to confirm the down-regulation 
of genes identified by canonical pathway analysis, probably 
because the small fold-changes were below detection levels. 
As loss of parvalbumin-positive interneurons is localized to the 
CA1 and CA2/3 hippocampal regions and not seen in the den-
tate gyrus of sub-chronic PCP-treated rats (Jenkins et al., 2010), 
measurement in the whole hippocampus used herein may have 
prevented detection of change by Q-PCR. Nonetheless, the data 
Figure 4. Pictorial representation of altered GABA receptor signaling due to PCP-SI treatment. The proteins highlighted (filled circle over-written with name as text) cor-
respond with mRNA levels found to be differentially expressed in PCP-SI rats following microarray analysis, all of which were identified as being down-regulated (see 
Table 2). Figure generated using Ingenuity Pathway Analysis (IPA, Ingenuity Systems Inc., QIAGEN). PCP-SI, phencyclidine-treated pups housed alone in social isolation.
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support the concept that facilitation of GABAergic activity may 
be a mechanism to develop future adjunctive therapeutics for 
schizophrenia (Lodge and Grace, 2011), which was evaluated in 
the current study by attempting to reverse behavioral deficits 
of PCP-SI rats using acute injection of lamotrigine. Increasing 
evidence from human genetic associations implies that genes 
implicated in schizophrenia show convergence on common bio-
logical pathways, such as the NMDA receptor signaling complex 
and voltage-gated calcium channels associated with the post-
synaptic density at glutamatergic synapsis involved in neuronal 
plasticity (Hall et al., 2015). Of note, the current microarray data 
(Supplementary Table S1) identified four gamma subunits of the 
L-type voltage-gated calcium channels to be down-regulated 
in PCP-SI rats, and single nucleotide polymorphisms in two of 
these (CACNG4 and CACNG6) have recently also been associated 
with schizophrenia (Guan et al., 2016). Conversely, many genes 
previously associated with schizophrenia do not appear in the 
list identified herein. This is not surprising since meta-analysis 
and genome-wide association studies show that thousands of 
common single nucleotide polymorphisms exist, but each has a 
small effect (odds ratios 1.1 to 1.2), only cumulatively explaining 
about 30% of the underlying genetic risk of schizophrenia (Allen 
et al., 2008; Ripke et al., 2013). Given the level of these associa-
tions, it would be surprising if the current analysis had sufficient 
power to identify individual genes, and instead has identified 
likely pathways affected.
In conclusion, neonatal PCP treatment combined with sub-
sequent isolation rearing of rats induces changes in expression 
of hippocampal genes regulating dopamine and GABA signaling 
and glutamate metabolism, several of which involve proteins 
strongly associated with schizophrenia. Acute lamotrigine treat-
ment partially reversed locomotor hyperactivity and (at the low 
dose) NOR impairment caused by PCP-SI. The relevance of these 
changes to the positive and cognitive symptoms of schizophre-
nia suggests that the therapeutic potential of drugs targeting 
voltage-gated sodium channels and modulating GABAergic and 
glutamatergic pathways as adjunctive therapy for schizophre-
nia is warranted.
Acknowledgments
The authors would like to thank Ian Topham and Stacy Knapp 
for technical assistance. We thank Takeda Cambridge Ltd for 
providing access to the Ingenuity Pathway Analysis software to 
produce Figure 4. This work was supported by the Biotechnology 
and Biological Sciences Research Council (to Dr Gaskin) and a 
Fellowship Recruitment Fund, The University of Nottingham 
(Dr Toledo-Rodriguez). The work was designed by Drs Fone and 
Gaskin and the latter performed the experiments. Dr Toledo-
Rodriguez designed the microarray study. Dr Alexander and Dr 
Toledo-Rodriguez assisted with the interpretation of the data 




Abazyan B, Nomura J, Kannan G, Ishizuka K, Tamashiro KL, Nuci-
fora F, Pogorelov V, Ladenheim B, Yang CX, Krasnova IN, Cadet 
JL, Pardo C, Mori S, Kamiya A, Vogel MW, Sawa A, Ross CA, 
Pletnikov MV (2010) Prenatal interaction of mutant DISC1 
and immune activation produces adult psychopathology. Biol 
Psychiatry 68:1172–1181.
Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Keg-
eles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gor-
man JM, Laruelle M (2000) Increased baseline occupancy of 
D-2 receptors by dopamine in schizophrenia. Proc Natl Acad 
Sci USA 97:8104–8109.
Adriano F, Caltagirone C, Spalletta G (2012) Hippocampal vol-
ume reduction in first-episode and chronic schizophrenia: a 
review and meta-analysis. Neuroscientist 18:180–200.
Allen NC, Bagade S, McQueen MB, Ioannidis JPA, Kavvoura FK, 
Khoury MJ, Tanzi RE, Bertram L (2008) Systematic meta-
analyses and field synopsis of genetic association studies in 
schizophrenia: the SzGene database. Nat Genet 40:827–834.
Arcego DM, Krolow R, Lampert C, Toniazzo AP, Berlitz C, Laz-
zaretti C, Schmitz F, Rodrigues AF, Wyse AT, Dalmaz C (2016) 
Early life adversities or high fat diet intake reduce cognitive 
function and alter BDNF signaling in adult rats: Interplay of 
these factors changes these effects. Int J Dev Neurosci 50:16–
25.
Ashby DM, Habib D, Dringenberg HC, Reynolds JN, Beninger RJ 
(2010) Subchronic MK-801 treatment and post-weaning social 
isolation in rats: differential effects on locomotor activity 
and hippocampal long-term potentiation. Behav Brain Res 
212:64–70.
Beasley CL, Reynolds GP (1997) Parvalbumin-immunoreactive 
neurons are reduced in the prefrontal cortex of schizophren-
ics. Schizophr Res 24:349–355.
Benes FM, Lim B, Matzilevich D, Walsh JP, Subburaju S, Minns M 
(2007) Regulation of the GABA cell phenotype in hippocam-
pus of schizophrenics and bipolars. Proc Natl Acad Sci USA 
104:10164–10169.
Bianchi M, Fone KCF, Azmi N, Heidbreder CA, Hagan JJ, Mars-
den CA (2006) Isolation rearing induces recognition memory 
deficits accompanied by cytoskeletal alterations in rat hip-
pocampus. Eur J Neurosci 24:2894–2902.
Borglum AD, Hampson M, Kjeldsen TE, Muir W, Murray V, Ewald 
H, Mors O, Blackwood D, Kruse TA (2001) Dopa decarboxylase 
genotypes may influence age at onset of schizophrenia. Mol 
Psychiatry 6:712–717.
Bourin M, Masse F, Hascoet M (2005) Evidence for the activity of 
lamotrigine at 5-HT1A receptors in the mouse forced swim-
ming test. J Psychiatry Neurosci 30:275–282.
Brauner JM, Hessler S, Groemer TW, Alzheimer C, Huth T (2014) 
Risperidone inhibits voltage-gated sodium channels. Eur J 
Pharmacol 728:100–106.
Brody SA, Conquet F, Geyer MA (2003a) Disruption of prepulse 
inhibition in mice lacking mGluR1. Eur J Neurosci 18:3361–
3366.
Brody SA, Geyer MA, Large CH (2003b) Lamotrigine prevents 
ketamine but not amphetamine-induced deficits in prepulse 
inhibition in mice. Psychopharmacology 169:240–246.
Calabresi P, Centonze D, Marfia GA, Pisani A, Bernardi G (1999) 
An in vitro electrophysiological study on the effects of phe-
nytoin, lamotrigine and gabapentin on striatal neurons. Br J 
Pharmacol 126:689–696.
Celikyurt IK, Ulak G, Mutlu O, Akar FY, Erden F, Komsuoglu SS 
(2012) Lamotrigine, a mood stabilizer, may have beneficial 
effects on memory acquisition and retrieval in mice. Life Sci 
91:1270–1274.
Del’ Guidice T, Beaulieu JM (2015) Selective disruption of dopa-
mine D2-receptors/beta-arrestin2 signaling by mood stabiliz-
ers. J Recept Signal Transduct Res 35:224–232.







Gaskin et al. | 11
Depoortere R et al (2005) Neurochemical, electrophysiological 
and pharmacological profiles of the selective inhibitor of 
the glycine transporter-I SSR504734, a potential new type 
of antipsychotic. Neuropsychopharmacology 30:1963–
1985.
Erfurth A, Walden J, Grunze H (1998) Lamotrigine in the treat-
ment of schizoaffective disorder. Neuropsychobiology 
38:204–205.
Fabricius K, Helboe L, Fink-Jensen A, Wortwein G, Steiniger-
Brach B (2010) Pharmacological characterization of social 
isolation-induced hyperactivity. Psychopharmacology (Berl) 
215:257–266.
Floresco SB, Todd CL, Grace AA (2001) Glutamatergic afferents 
from the hippocampus to the nucleus accumbens regulate 
activity of ventral tegmental area dopamine neurons. J Neu-
rosci 21:4915–4922.
Fone KC, Porkess MV (2008) Behavioural and neurochemical 
effects of post-weaning social isolation in rodents-relevance 
to developmental neuropsychiatric disorders. Neurosci 
Biobehav Rev 32:1087–1102.
Gaskin PLR, Alexander SPH, Fone KCF (2014) Neonatal phency-
clidine administration and post-weaning social isolation as 
a dual-hit model of ‘schizophrenia-like’ behaviour in the rat. 
Psychopharmacology 231:2533–2545.
Gilabert-Juan J, Molto MD, Nacher J (2012) Post-weaning social 
isolation rearing influences the expression of molecules 
related to inhibitory neurotransmission and structural plas-
ticity in the amygdala of adult rats. Brain Res 1448:129–136.
Giovanoli S, Engler H, Engler A, Richetto J, Voget M, Willi R, Win-
ter C, Riva MA, Mortensen PB, Schedlowski M, Meyer U (2013) 
Stress in puberty unmasks latent neuropathological con-
sequences of prenatal immune activation in mice. Science 
339:1095–1099.
Goff DC (2009) Review: lamotrigine may be an effective treat-
ment for clozapine resistant schizophrenia. Evid Based Ment 
Health 12:111–111.
Grayson B, Barnes SA, Markou A, Piercy C, Podda G, Neill JC 
(2015) Postnatal phencyclidine (PCP) as a neurodevelop-
mental animal model of schizophrenia pathophysiology 
and symptomatology: a review. Curr Top Behav Neurosci. 
doi:10.1007/7854_2015_403. 
Guan F, Zhang T, Liu X, Han W, Lin H, Li L, Chen G, Li T (2016) Eval-
uation of voltage-dependent calcium channel gamma gene 
families identified several novel potential susceptible genes 
to schizophrenia. Sci Rep 6:24914.
Hall J, Trent S, Thomas KL, O’Donovan MC, Owen MJ (2015) 
Genetic risk for schizophrenia: convergence on synaptic 
pathways involved in plasticity. Biol Psychiatry 77:52–58.
Hardingham GE, Do KQ (2016) Linking early-life NMDAR hypo-
function and oxidative stress in schizophrenia pathogenesis. 
Nat Rev Neurosci 17:1–9.
Harrison P, Law A (2006) Neuregulin 1 and schizophrenia: genet-
ics, gene expression, and neurobiology. Biol Psychiatry 
60:132–140.
Harrison PJ (2015) Recent genetic findings in schizophrenia and 
their therapeutic relevance. J Psychopharmacol 29:85–96.
Harte MK, Powell SB, Swerdlow NR, Geyer MA, Reynolds GP (2007) 
Deficits in parvalbumin and calbindin immunoreactive cells 
in the hippocampus of isolation reared rats. J Neural Transm 
114:893–898.
Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z, 
Sampson AR, Lewis DA (2003) Gene expression deficits in a 
subclass of GABA neurons in the prefrontal cortex of subjects 
with schizophrenia. J Neurosci 23:6315–6326.
Heckers S, Konradi C (2010) Hippocampal pathology in schizo-
phrenia. In: Behavioral Neurobiology of Schizophrenia and Its 
Treatment (Swerdlow NR, ed.), pp 529–553.
Heckers S, Rauch SL, Goff D, Savage CR, Schacter DL, Fischman 
AJ, Alpert NM (1998) Impaired recruitment of the hippocam-
pus during conscious recollection in schizophrenia. Nat Neu-
rosc 1:318–323.
Hickey AJ, Reynolds JN, Beninger RJ (2012) Post-weaning social 
isolation and subchronic NMDA glutamate receptor block-
ade: Effects on locomotor activity and GABA signaling in the 
rat suggest independent mechanisms. Pharmacol Biochem 
Behav 101:231–238.
Hoogendoorn MLC, Bakker SC, Schnack HG, Selten JPC, Otten HG, 
Verduijn W, van der Heijden F, Pearson PL, Kahn RS, Sinke RJ 
(2005) No association between 12 dopaminergic genes and 
schizophrenia in a large Dutch sample. Am J Med Genet B 
Neuropsychiatr Genet 134B:6–9.
Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham 
A, Kapur S (2012) The nature of dopamine dysfunction in 
schizophrenia and what this means for treatment. Arch Gen 
Psychiatry 69:776–786.
Howes OD, Kapur S (2009) The dopamine hypothesis of schizo-
phrenia: version III - the final common pathway. Schizophr 
Bull 35:549–562.
Ibi D, Takuma K, Koike H, Mizoguchi H, Tsuritani K, Kuwahara Y, 
Kamei H, Nagai T, Yoneda Y, Nabeshima T, Yamada K (2008) 
Social isolation rearing-induced impairment of the hip-
pocampal neurogenesis is associated with deficits in spatial 
memory and emotion-related behaviors in juvenile mice. J 
Neurochem 105:921–932.
Iwata N, Ozaki N, Inada T, Goldman D (2001) Association of a 
5-HT5A receptor polymorphism, Pro15Ser, to schizophrenia. 
Mol Psychiatry 6:217–219.
Jenkins TA, Harte MK, Reynolds GP (2010) Effect of subchronic 
phencyclidine administration on sucrose preference and hip-
pocampal parvalbumin immunoreactivity in the rat. Neuro-
sci Lett 471:144–147.
Jevtic G, Nikolic T, Mircic A, Stojkovic T, Velimirovic M, Trajkovic V, 
Markovic I, Trbovich AM, Radonjic NV, Petronijevic ND (2016) 
Mitochondrial impairment, apoptosis and autophagy in a rat 
brain as immediate and long-term effects of perinatal phen-
cyclidine treatment—influence of restraint stress. Prog Neu-
ropsychopharmacol Biol Psychiatry 66:87–96.
Jones CA, Watson DJG, Fone KCF (2011) Animal models of schizo-
phrenia. Br J Pharmacol 164:1162–1194.
Kaalund SS, Riise J, Broberg BV, Fabricius K, Karlsen AS, Secher T, 
Plath N, Pakkenberg B (2013) Differential expression of par-
valbumin in neonatal phencyclidine-treated rats and socially 
isolated rats. J Neurochem 124:548–557.
Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold 
JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, 
Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, 
Lieberman JA (2007) Neurocognitive effects of antipsychotic 
medications in patients with chronic schizophrenia in the 
CATIE Trial. Arch Gen Psychiatry 64:633–647.
King MV, Sleight AJ, Woolley ML, Topham IA, Marsden CA, Fone 
KCF (2004) 5-HT6 receptor antagonists reverse delay-depend-
ent deficits in novel object discrimination by enhancing 
consolidation—an effect sensitive to NMDA receptor antago-
nism. Neuropharmacology 47:195–204.
Kinney JW, Davis CN, Tabarean I, Conti B, Bartfai T, Behrens MM 
(2006) A specific role for NR2A-containing NMDA receptors in 
the maintenance of parvalbumin and GAD67 immunoreac-
tivity in cultured interneurons. J Neurosci 26:1604–1615.







12 | International Journal of Neuropsychopharmacology, 2016
Kjaerby C, Broberg BV, Kristiansen U, Dalby NO (2014) Impaired 
GABAergic inhibition in the prefrontal cortex of early post-
natal phencyclidine (PCP)-treated rats. Cereb Cortex 24:2522–
2532.
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner 
JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanes-
thetic effects of the noncompetitive NMDA antagonist, keta-
mine, in humans. Psychotomimetic, perceptual, cognitive, 
and neuroendocrine responses. Arch Gen Psychiatry 51:199–
214.
Lahti AC, Koffel B, Laporte D, Tamminga CA (1995) Subanaes-
thetic doses of ketamine stimulate psychosis in schizophre-
nia. Neuropsychopharmacology 13:9–19.
Large CH, Bison S, Sartori I, Read KD, Gozzi A, Quarta D, Antolini 
M, Hollands E, Gill CH, Gunthorpe MJ, Idris N, Neill JC, Alvaro 
GS (2011) The efficacy of sodium channel blockers to pre-
vent phencyclidine-induced cognitive dysfunction in the rat: 
potential for novel treatments for schizophrenia. J Pharm Exp 
Ther 338:100–113.
Leach MJ, Baxter MG, Critchley MAE (1991) Neurochemical and 
behavioral aspects of lamatrogine. Epilepsia 32:S4–S8.
Leifker FR, Bowie CR, Harvey PD (2009) Determinants of every-
day outcomes in schizophrenia: The influences of cognitive 
impairment, functional capacity, and symptoms. Schizophr 
Res 115:82–87.
Lim AL, Taylor DA, Malone DT (2012) A  two-hit model: behav-
ioural investigation of the effect of combined neonatal 
MK-801 administration and isolation rearing in the rat. J Psy-
chopharmacol 26:1252–1264.
Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, 
Grace AA (2008) Circuit-based framework for understanding 
neurotransmitter and risk gene interactions in schizophre-
nia. Trends Neurosci 31:234–242.
Liu F, Zou X, Sadovova N, Zhang X, Shi L, Guo L, Qian F, Wen Z, 
Patterson TA, Hanig JP, Paule MG, Slikker W Jr., Wang C (2010) 
Changes in gene expression after phencyclidine administra-
tion in developing rats: a potential animal model for schizo-
phrenia. Int J Dev Neurosci 29:351–358.
Lodge DJ, Grace AA (2009) Gestational methylazoxymethanol 
acetate administration: A  developmental disruption model 
of schizophrenia. Behav Brain Res 204:306–312.
Lodge DJ, Grace AA (2011) Hippocampal dysregulation of dopa-
mine system function and the pathophysiology of schizo-
phrenia. Trends Pharmacol Sci 32:507–513.
Lyon L, Saksida LM, Bussey TJ (2012) Spontaneous object recogni-
tion and its relevance to schizophrenia: a review of findings 
from pharmacological, genetic, lesion and developmental 
rodent models. Psychopharmacology 220:647–672.
Maksimovic M, Vekovischeva OY, Aitta-aho T, Korpi ER (2014) 
Chronic treatment with mood-stabilizers attenuates abnor-
mal hyperlocomotion of GluA1-subunit deficient mice. PLOS 
One 9:e100188.
McIntosh AL, Ballard TM, Steward LJ, Moran PM, Fone KCF (2013) 
The atypical antipsychotic risperidone reverses the recogni-
tion memory deficits induced by post-weaning social isola-
tion in rats. Psychopharmacology 228:31–42.
McKibben CE, Jenkins TA, Adams HN, Harte MK, Reynolds GP 
(2010) Effect of pretreatment with risperidone on phencycli-
dine-induced disruptions in object recognition memory and 
prefrontal cortex parvalbumin immunoreactivity in the rat. 
Behav Brain Res 208:132–136.
Meyer U (2014) Prenatal Poly(I:C) Exposure and Other Develop-
mental Immune Activation Models in Rodent Systems. Biol 
Psychiatry 75:307–315.
Millan MJ, Bales KL (2013) Towards improved animal models for 
evaluating social cognition and its disruption in schizophre-
nia: The CNTRICS initiative. Neurosci Biobehav Rev 37:2166–
2180.
Nakato Y, Abekawa T, Ito K, Inoue T, Koyama T (2010) Lamotrigine 
blocks the initiation and expression of repeated high-dose 
methamphetamine-induced prepulse inhibition deficit in 
rats. Neurosci Lett 481:183–187.
Napolitano A, Shah K, Schubert MI, Porkess V, Fone KC, Auer 
DP (2013) In vivo neurometabolic profiling to characterize 
the effects of social isolation and ketamine-induced NMDA 
antagonism: a rodent study at 7.0 T. Schizophr Bull 40:566–
574.
Radonjic NV, Jakovcevski I, Bumbasirevic V, Petronijevic ND 
(2013) Perinatal phencyclidine administration decreases the 
density of cortical interneurons and increases the expression 
of neuregulin-1. Psychopharmacology 227:673–683.
Rajagopal L, Massey BW, Huang M, Oyamada Y, Meltzer HY 
(2014) The novel object recognition test in rodents in relation 
to cognitive impairment in schizophrenia. Curr Pharm Des 
20:5104–5114.
Reid JG, Gitlin MJ, Altshuler LL (2013) Lamotrigine in psychiatric 
disorders. J Clin Psychiatry 74:675–684.
Ripke S et al. (2013) Genome-wide association analysis identi-
fies 13 new risk loci for schizophrenia. Nat Genet 45:1150–
1159.
Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, 
Asllani I, Inbar BP, Corcoran CM, Lieberman JA, Moore H, 
Small SA (2013) Imaging patients with psychosis and a 
mouse model establishes a spreading pattern of hippocam-
pal dysfunction and implicates Ggutamate as a driver. Neu-
ron 78:81–93.
Schubert MI, Porkess MV, Dashdorj N, Fone KCF, Auer DP (2009) 
Effects of social isolation rearing on the limbic brain: a com-
bined behavioral and magnetic resonance imaging volume-
try study in rats. Neuroscience 159:21–30.
Shannon HE, Love PL (2004) Effects of antiepileptic drugs on 
working memory as assessed by spatial alternation perfor-
mance in rats. Epilepsy Behav 5:857–865.
Shannon HE, Love PL (2005) Effects of antiepileptic drugs on 
attention as assessed by a five-choice serial reaction time 
task in rats. Epilepsy Behav 7:620–628.
Sharma RP, Janicak PG, Bissette G, Nemeroff CB (1997) CSF 
neurotensin concentrations and antipsychotic treatment 
in schizophrenia and schizoaffective disorder. Am J Psych 
154:1019–1021.
Simpson SM, Menard JL, Reynolds JN, Beninger RJ (2010) Post-
weaning social isolation increases activity in a novel envi-
ronment but decreases defensive burying and subchronic 
MK-801 enhances the activity but not the burying effect in 
rats. Pharmacol Biochem Behav 95:72–79.
Talkowski ME, Kirov G, Bamne M, Georgieva L, Torres G, Man-
sour H, Chowdari KV, Milanova V, Wood J, McClain L, Prasad 
K, Shirts B, Zhang J, O’Donovan MC, Owen MJ, Devlin B, Nim-
gaonkar VL (2008) A network of dopaminergic gene variations 
implicated as risk factors for schizophrenia. Hum Mol Gen 
17:747–758.
Tamminga CA, Stan AD, Wagner AD (2010) The hippocampal for-
mation in schizophrenia. Am J Psych 167:1178–1193.
Tiihonen J, Wahlbeck K, Kiviniemi V (2009) The efficacy of lamo-
trigine in clozapine-resistant schizophrenia: a systematic 
review and meta-analysis. Schizophr Res 109:10–14.
Tregellas JR, Smucny J, Harris JG, Olincy A, Maharajh K, Kron-
berg E, Eichman LC, Lyons E, Freedman R (2014) Intrinsic 







Gaskin et al. | 13
hippocampal activity as a biomarker for cognition and symp-
toms in schizophrenia. Am J Psych 171:549–556.
Turnock-Jones JJ, Jennings CA, Robbins MJ, Cluderay JE, Cilia J, 
Reid JL, Taylor A, Jones DNC, Emson PC, Southam E (2009) 
Increased expression of the NR2A NMDA receptor subunit 
in the prefrontal cortex of rats reared in isolation. Synapse 
63:836–846.
Varty GB, Marsden CA, Higgins GA (1999) Reduced synaptophy-
sin immunoreactivity in the dentate gyrus of prepulse inhi-
bition-impaired isolation-reared rats. Brain Res 824:197–203.
Vayisoglu S, Yagcioglu AEA, Yagcioglu S, Karahan S, Karci O, Gurel 
SC, Yazici MK (2013) Lamotrigine augmentation in patients 
with schizophrenia who show partial response to clozapine 
treatment. Schizophr Res 143:207–214.
Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley 
JL, Johnson KM (2001) Long-term behavioral and neurode-
generative effects of perinatal phencyclidine administration: 
Implications for schizophrenia. Neuroscience 107:535–550.
Wang CZ, Yang SF, Xia Y, Johnson KM (2008) Postnatal phencycli-
dine administration selectively reduces adult cortical parval-
bumin-containing interneurons. Neuropsychopharmacology 
33:2442–2455.
Watson DJG, Marsden CA, Millan MJ, Fone KCF (2012) Blockade of 
dopamine D-3 but not D-2 receptors reverses the novel object 
discrimination impairment produced by post-weaning social 
isolation: implications for schizophrenia and its treatment. 
Int J Neuropsychop 15:471–484.
Watson DJ, King MV, Gyertyan I, Kiss B, Adham N, Fone KC (2016) 
The dopamine D3-preferring D2/D3 dopamine receptor par-
tial agonist, cariprazine, reverses behavioural changes in a rat 
neurodevelopmental model for schizophrenia. Eur Neuropsy-
chopharmacol 26:208–224.
Williams HJ, Zamzow CR, Robertson H, Dursun SM (2006) Effects 
of clozapine plus lamotrigine on phencyclidine-induced 
hyperactivity. Prog Neuropsychopharmacol Biol Psychiatry 
30:239–243.
Zheng C, Yang K, Liu Q, Wang M-Y, Shen J, Sofia Valles A, Lukas RJ, 
Barrantes FJ, Wu J (2010) The anticonvulsive drug lamotrigine 
blocks neuronal alpha 4 beta 2 nicotinic acetylcholine recep-
tors. J Pharm Exp Ther 335:401–408.
 by guest on O
ctober 19, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
